SCHEMBL4043996

SCHEMBL4043996

CC(C)CC(NC(=O)c1ccc(-c2ccccc2)s1)C(=O)N1CCC2C1C(=O)CN2C(=O)Nc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 5/20 0.55
HPGDS O60760 2/20 0.44
NPC1 O15118 1/20 0.42
PPARG P37231 1/20 0.42
RAB9A P51151 1/20 0.42
NCOA2 Q15596 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
CTSS P25774 2/20 0.41
CTSB P07858 1/20 0.41
CHRNA7 P36544 5/20 0.40
HTR3E A5X5Y0 4/20 0.40
HTR3B O95264 4/20 0.40
HTR3A P46098 4/20 0.40
HTR3D Q70Z44 4/20 0.40
HTR3C Q8WXA8 4/20 0.40
TP53 P04637 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
F10 P00742 1/20 0.39
MAPT P10636 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040699 0.91 CTSK (0.55) CTSKHPGDSCTSSCTSBCHRNA7
SCHEMBL4045241 0.89 CTSK (0.55) CTSKHPGDSNPC1RAB9ACTSS
SCHEMBL4042777 0.89 CTSK (0.57) CTSKHPGDSNPC1RAB9ACTSS
SCHEMBL4040231 0.89 CTSK (0.56) CTSKHPGDSNPC1RAB9ACTSS
SCHEMBL8349299 0.89 CTSK (0.70) CTSKHPGDSNPC1RAB9ACTSS
SCHEMBL4044153 0.89 CTSK (0.70) CTSKHPGDSNPC1RAB9ACTSS
SCHEMBL4039384 0.89 CTSK (0.56) CTSKHPGDSNPC1RAB9ACTSS
SCHEMBL4039928 0.88 CTSK (0.54) CTSKHPGDSNPC1RAB9ACTSS
SCHEMBL4043010 0.88 CTSK (0.55) CTSKHPGDSNPC1RAB9ACTSS
SCHEMBL4043626 0.88 CTSK (0.48) CTSKHPGDSNPC1PPARGRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP claimed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP disclosed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885HPGDS 603/4885NPC1 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.